GlassScriptPhysician profile
Jeffrey Douglas Cotter
NPI 1861811085
$4,829.63
in general payments reported to CMS, 2019-2025
26 companies · $1,697 in 2025
The $1,697 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.47 · 2022: $422 · 2023: $1,151 · 2024: $1,540 · 2025: $1,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,388.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $895.13 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $721.56 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $643.90 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $430.88 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $378.66 | 2022-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $253.46 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Abbvie INC. | $223.90 | 2022-2025 | Ubrelvy, Qulipta, Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $221.48 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $169.13 | 2022-2024 | Xarelto |
| Glaxosmithkline, LLC. | $152.02 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $114.97 | 2024-2025 | Veozah |
| Medtronic, INC. | $96.86 | 2025 | Intellis Adaptivestim |
| Exact Sciences Corporation | $93.23 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $91.63 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $49.20 | 2022-2025 | Eliquis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $48.83 | 2024-2025 | Omnipod |
| Seqirus USA INC | $45.13 | 2025 | Flucelvax, Fluad |
| Xeris Pharmaceuticals, INC. | $35.77 | 2024-2025 | Gvoke Hypopen |
| Amgen INC. | $31.66 | 2024-2025 | Evenity, Prolia |
| Neos Therapeutics, LP | $26.51 | 2022 | |
| Inspire Medical Systems, INC. | $21.70 | 2024 | Inspire |
| Antares Pharma, INC. | $20.40 | 2025 | Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.39 | 2024 | Jardiance |
| Tolmar, INC. | $15.85 | 2024 | |
| Cranial Technologies, INC | $15.28 | 2025 | Doc Band |
| Phathom Pharmaceuticals, INC. | $13.10 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Cotter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.